CA2931850A1 - Alkylpyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof - Google Patents

Info

Publication number

CA2931850A1

CA2931850A1 CA2931850A CA2931850A CA2931850A1 CA 2931850 A1 CA2931850 A1 CA 2931850A1 CA 2931850 A CA2931850 A CA 2931850A CA 2931850 A CA2931850 A CA 2931850A CA 2931850 A1 CA2931850 A1 CA 2931850A1

Authority

CA

Canada

Prior art keywords

compound

chloro

fluoro

juvenile

disease

Prior art date

2013-12-10

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 230000001225 therapeutic effect Effects 0.000 title description 16
• ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 title description 8
• CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 title description 5
• SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 title description 5
• 239000000362 adenosine triphosphatase inhibitor Substances 0.000 title description 3
• 238000000034 method Methods 0.000 claims abstract description 83
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 47
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 29
• 201000011510 cancer Diseases 0.000 claims abstract description 17
• 208000026278 immune system disease Diseases 0.000 claims abstract description 11
• 150000001875 compounds Chemical class 0.000 claims description 191
• -1 3-chloro-5-fluorophenyl Chemical group 0.000 claims description 91
• 125000001309 chloro group Chemical group Cl* 0.000 claims description 48
• 125000001153 fluoro group Chemical group F* 0.000 claims description 44
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 33
• 208000035475 disorder Diseases 0.000 claims description 32
• 229910052739 hydrogen Inorganic materials 0.000 claims description 31
• 239000001257 hydrogen Substances 0.000 claims description 31
• 150000003839 salts Chemical class 0.000 claims description 28
• 239000008194 pharmaceutical composition Substances 0.000 claims description 24
• 125000001424 substituent group Chemical group 0.000 claims description 19
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 15
• 201000010099 disease Diseases 0.000 claims description 14
• 125000001188 haloalkyl group Chemical group 0.000 claims description 14
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 14
• 201000004681 Psoriasis Diseases 0.000 claims description 13
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 13
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 12
• 230000000366 juvenile effect Effects 0.000 claims description 12
• 208000011231 Crohn disease Diseases 0.000 claims description 11
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 10
• 239000003937 drug carrier Substances 0.000 claims description 9
• 230000002438 mitochondrial effect Effects 0.000 claims description 9
• 208000003456 Juvenile Arthritis Diseases 0.000 claims description 8
• 201000006417 multiple sclerosis Diseases 0.000 claims description 8
• 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 8
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 7
• 208000011580 syndromic disease Diseases 0.000 claims description 7
• 208000035143 Bacterial infection Diseases 0.000 claims description 6
• 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
• 206010025323 Lymphomas Diseases 0.000 claims description 6
• 206010039710 Scleroderma Diseases 0.000 claims description 6
• 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
• 208000022362 bacterial infectious disease Diseases 0.000 claims description 6
• 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 6
• 208000024891 symptom Diseases 0.000 claims description 6
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 5
• 201000001320 Atherosclerosis Diseases 0.000 claims description 5
• 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
• 208000006673 asthma Diseases 0.000 claims description 5
• 201000001981 dermatomyositis Diseases 0.000 claims description 5
• 206010028417 myasthenia gravis Diseases 0.000 claims description 5
• 201000000050 myeloid neoplasm Diseases 0.000 claims description 5
• 206010003253 Arthritis enteropathic Diseases 0.000 claims description 4
• 206010003267 Arthritis reactive Diseases 0.000 claims description 4
• 208000015943 Coeliac disease Diseases 0.000 claims description 4
• 208000034189 Sclerosis Diseases 0.000 claims description 4
• 208000021386 Sjogren Syndrome Diseases 0.000 claims description 4
• 206010047115 Vasculitis Diseases 0.000 claims description 4
• 208000019069 chronic childhood arthritis Diseases 0.000 claims description 4
• 230000036566 epidermal hyperplasia Effects 0.000 claims description 4
• 229910052736 halogen Inorganic materials 0.000 claims description 4
• 230000002401 inhibitory effect Effects 0.000 claims description 4
• 208000002574 reactive arthritis Diseases 0.000 claims description 4
• 230000009885 systemic effect Effects 0.000 claims description 4
• 230000001732 thrombotic effect Effects 0.000 claims description 4
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
• 208000015023 Graves' disease Diseases 0.000 claims description 3
• 206010061218 Inflammation Diseases 0.000 claims description 3
• 206010037549 Purpura Diseases 0.000 claims description 3
• 241001672981 Purpura Species 0.000 claims description 3
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
• 208000024340 acute graft versus host disease Diseases 0.000 claims description 3
• 208000017760 chronic graft versus host disease Diseases 0.000 claims description 3
• 208000027866 inflammatory disease Diseases 0.000 claims description 3
• 230000004054 inflammatory process Effects 0.000 claims description 3
• 201000008482 osteoarthritis Diseases 0.000 claims description 3
• 239000012453 solvate Substances 0.000 claims description 3
• 230000003582 thrombocytopenic effect Effects 0.000 claims description 3
• 208000026872 Addison Disease Diseases 0.000 claims description 2
• 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
• 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 2
• 208000023328 Basedow disease Diseases 0.000 claims description 2
• 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 2
• 201000004624 Dermatitis Diseases 0.000 claims description 2
• 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 2
• 208000012528 Juvenile dermatomyositis Diseases 0.000 claims description 2
• 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims description 2
• 208000020410 Psoriasis-related juvenile idiopathic arthritis Diseases 0.000 claims description 2
• 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
• 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
• 208000012322 Raynaud phenomenon Diseases 0.000 claims description 2
• 206010046851 Uveitis Diseases 0.000 claims description 2
• 206010003230 arteritis Diseases 0.000 claims description 2
• 206010003246 arthritis Diseases 0.000 claims description 2
• 201000008937 atopic dermatitis Diseases 0.000 claims description 2
• 210000000988 bone and bone Anatomy 0.000 claims description 2
• 210000000845 cartilage Anatomy 0.000 claims description 2
• 230000015556 catabolic process Effects 0.000 claims description 2
• 201000010415 childhood type dermatomyositis Diseases 0.000 claims description 2
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 2
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
• 238000006731 degradation reaction Methods 0.000 claims description 2
• 201000004990 juvenile ankylosing spondylitis Diseases 0.000 claims description 2
• 208000012102 polyarticular juvenile rheumatoid arthritis Diseases 0.000 claims description 2
• 201000000306 sarcoidosis Diseases 0.000 claims description 2
• 208000010157 sclerosing cholangitis Diseases 0.000 claims description 2
• 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
• 125000005843 halogen group Chemical group 0.000 claims 1
• OYRIUGCJZVFCAV-UHFFFAOYSA-N 2-(1h-pyrazol-5-yl)guanidine Chemical class NC(=N)NC=1C=CNN=1 OYRIUGCJZVFCAV-UHFFFAOYSA-N 0.000 abstract description 22
• 239000003814 drug Substances 0.000 abstract description 20
• 229940124597 therapeutic agent Drugs 0.000 abstract description 7
• 230000004968 inflammatory condition Effects 0.000 abstract description 6
• 239000000203 mixture Substances 0.000 description 68
• 239000003795 chemical substances by application Substances 0.000 description 62
• 210000004027 cell Anatomy 0.000 description 59
• 101150041968 CDC13 gene Proteins 0.000 description 42
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 42
• DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 42
• DTQVDTLACAAQTR-DYCDLGHISA-N trifluoroacetic acid-d1 Chemical compound [2H]OC(=O)C(F)(F)F DTQVDTLACAAQTR-DYCDLGHISA-N 0.000 description 41
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 39
• 238000009472 formulation Methods 0.000 description 30
• 230000006907 apoptotic process Effects 0.000 description 29
• 238000004128 high performance liquid chromatography Methods 0.000 description 25
• 238000012360 testing method Methods 0.000 description 21
• 239000004480 active ingredient Substances 0.000 description 18
• 230000000694 effects Effects 0.000 description 18
• 239000000243 solution Substances 0.000 description 16
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
• 238000002560 therapeutic procedure Methods 0.000 description 15
• UMGDCJDMYOKAJW-UHFFFAOYSA-N aminothiocarboxamide Natural products NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 14
• 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 13
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
• 125000000217 alkyl group Chemical group 0.000 description 11
• 229910052799 carbon Inorganic materials 0.000 description 11
• 230000008482 dysregulation Effects 0.000 description 11
• 238000004949 mass spectrometry Methods 0.000 description 11
• 239000003921 oil Substances 0.000 description 11
• 125000003226 pyrazolyl group Chemical group 0.000 description 11
• 210000001519 tissue Anatomy 0.000 description 11
• 150000002357 guanidines Chemical class 0.000 description 10
• 235000019198 oils Nutrition 0.000 description 10
• 239000007787 solid Substances 0.000 description 10
• 241001465754 Metazoa Species 0.000 description 9
• 150000001721 carbon Chemical group 0.000 description 9
• 230000030833 cell death Effects 0.000 description 9
• 238000011260 co-administration Methods 0.000 description 9
• 230000012010 growth Effects 0.000 description 9
• 239000007788 liquid Substances 0.000 description 9
• 238000002360 preparation method Methods 0.000 description 9
• 239000000047 product Substances 0.000 description 9
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
• 125000003636 chemical group Chemical group 0.000 description 8
• 238000010790 dilution Methods 0.000 description 8
• 239000012895 dilution Substances 0.000 description 8
• 229940079593 drug Drugs 0.000 description 8
• 238000003556 assay Methods 0.000 description 7
• 230000001580 bacterial effect Effects 0.000 description 7
• 230000008901 benefit Effects 0.000 description 7
• 239000000839 emulsion Substances 0.000 description 7
• 239000012071 phase Substances 0.000 description 7
• ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 7
• 239000000843 powder Substances 0.000 description 7
• 230000008569 process Effects 0.000 description 7
• 108090000623 proteins and genes Proteins 0.000 description 7
• 239000011541 reaction mixture Substances 0.000 description 7
• 239000002904 solvent Substances 0.000 description 7
• 239000000725 suspension Substances 0.000 description 7
• 239000003826 tablet Substances 0.000 description 7
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
• 241000894006 Bacteria Species 0.000 description 6
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
• 208000009329 Graft vs Host Disease Diseases 0.000 description 6
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 6
• 241000700159 Rattus Species 0.000 description 6
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
• 230000001594 aberrant effect Effects 0.000 description 6
• 239000002253 acid Substances 0.000 description 6
• 239000002585 base Substances 0.000 description 6
• 210000004369 blood Anatomy 0.000 description 6
• 239000008280 blood Substances 0.000 description 6
• 238000006243 chemical reaction Methods 0.000 description 6
• 239000000460 chlorine Chemical group 0.000 description 6
• 230000001684 chronic effect Effects 0.000 description 6
• 239000003085 diluting agent Substances 0.000 description 6
• 208000024908 graft versus host disease Diseases 0.000 description 6
• 230000001965 increasing effect Effects 0.000 description 6
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
• 239000003381 stabilizer Substances 0.000 description 6
• 208000023275 Autoimmune disease Diseases 0.000 description 5
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
• 241000699670 Mus sp. Species 0.000 description 5
• 206010028851 Necrosis Diseases 0.000 description 5
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
• 208000036142 Viral infection Diseases 0.000 description 5
• 239000013543 active substance Substances 0.000 description 5
• 125000003545 alkoxy group Chemical group 0.000 description 5
• 150000001412 amines Chemical class 0.000 description 5
• 239000000969 carrier Substances 0.000 description 5
• 230000010261 cell growth Effects 0.000 description 5
• 239000000306 component Substances 0.000 description 5
• 239000006071 cream Substances 0.000 description 5
• 239000003995 emulsifying agent Substances 0.000 description 5
• 239000003925 fat Substances 0.000 description 5
• 235000019197 fats Nutrition 0.000 description 5
• 239000008187 granular material Substances 0.000 description 5
• 230000003463 hyperproliferative effect Effects 0.000 description 5
• 230000005764 inhibitory process Effects 0.000 description 5
• 210000004698 lymphocyte Anatomy 0.000 description 5
• 230000017074 necrotic cell death Effects 0.000 description 5
• 241000894007 species Species 0.000 description 5
• 230000009385 viral infection Effects 0.000 description 5
• 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 4
• KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 4
• KJEPTDZALITTEZ-LNKPDPKZSA-M C(#N)\C(=C(\C(F)(F)F)/[O-])\C.[K+] Chemical compound C(#N)\C(=C(\C(F)(F)F)/[O-])\C.[K+] KJEPTDZALITTEZ-LNKPDPKZSA-M 0.000 description 4
• 239000000443 aerosol Substances 0.000 description 4
• 238000010171 animal model Methods 0.000 description 4
• 239000003146 anticoagulant agent Substances 0.000 description 4
• 230000001640 apoptogenic effect Effects 0.000 description 4
• 230000015572 biosynthetic process Effects 0.000 description 4
• 230000004663 cell proliferation Effects 0.000 description 4
• 230000001413 cellular effect Effects 0.000 description 4
• 239000003153 chemical reaction reagent Substances 0.000 description 4
• 238000004587 chromatography analysis Methods 0.000 description 4
• 229940093499 ethyl acetate Drugs 0.000 description 4
• 235000019439 ethyl acetate Nutrition 0.000 description 4
• 239000004615 ingredient Substances 0.000 description 4
• 239000003112 inhibitor Substances 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 239000000543 intermediate Substances 0.000 description 4
• 229910052740 iodine Inorganic materials 0.000 description 4
• 206010025135 lupus erythematosus Diseases 0.000 description 4
• 230000014759 maintenance of location Effects 0.000 description 4
• 229910052757 nitrogen Inorganic materials 0.000 description 4
• 239000003960 organic solvent Substances 0.000 description 4
• 210000002381 plasma Anatomy 0.000 description 4
• 229940116357 potassium thiocyanate Drugs 0.000 description 4
• 239000000741 silica gel Substances 0.000 description 4
• 229910002027 silica gel Inorganic materials 0.000 description 4
• 230000002407 ATP formation Effects 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
• PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 3
• 206010059866 Drug resistance Diseases 0.000 description 3
• 241000725303 Human immunodeficiency virus Species 0.000 description 3
• 206010054949 Metaplasia Diseases 0.000 description 3
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
• 238000005481 NMR spectroscopy Methods 0.000 description 3
• 241000700605 Viruses Species 0.000 description 3
• 150000007513 acids Chemical class 0.000 description 3
• 230000003213 activating effect Effects 0.000 description 3
• 230000004075 alteration Effects 0.000 description 3
• 238000004458 analytical method Methods 0.000 description 3
• 229940121363 anti-inflammatory agent Drugs 0.000 description 3
• 239000002260 anti-inflammatory agent Substances 0.000 description 3
• 239000002220 antihypertensive agent Substances 0.000 description 3
• 229940030600 antihypertensive agent Drugs 0.000 description 3
• 230000033228 biological regulation Effects 0.000 description 3
• 239000012267 brine Substances 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 230000000875 corresponding effect Effects 0.000 description 3
• 230000006378 damage Effects 0.000 description 3
• 230000002939 deleterious effect Effects 0.000 description 3
• 238000011161 development Methods 0.000 description 3
• 230000018109 developmental process Effects 0.000 description 3
• 239000012636 effector Substances 0.000 description 3
• 150000002148 esters Chemical class 0.000 description 3
• 150000002367 halogens Chemical class 0.000 description 3
• 238000001727 in vivo Methods 0.000 description 3
• 230000001939 inductive effect Effects 0.000 description 3
• 238000007918 intramuscular administration Methods 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 230000015689 metaplastic ossification Effects 0.000 description 3
• 239000012044 organic layer Substances 0.000 description 3
• 239000006072 paste Substances 0.000 description 3
• 230000002062 proliferating effect Effects 0.000 description 3
• 102000004169 proteins and genes Human genes 0.000 description 3
• 230000005855 radiation Effects 0.000 description 3
• 239000002464 receptor antagonist Substances 0.000 description 3
• 229940044551 receptor antagonist Drugs 0.000 description 3
• 230000019491 signal transduction Effects 0.000 description 3
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
• 239000007858 starting material Substances 0.000 description 3
• 239000011550 stock solution Substances 0.000 description 3
• 238000006467 substitution reaction Methods 0.000 description 3
• 238000011200 topical administration Methods 0.000 description 3
• 231100000331 toxic Toxicity 0.000 description 3
• 230000002588 toxic effect Effects 0.000 description 3
• 230000003612 virological effect Effects 0.000 description 3
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
• OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 2
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
• YTARZCOGKBEMSD-UHFFFAOYSA-N 4-methyl-5-(trifluoromethyl)-1h-pyrazol-3-amine Chemical compound CC=1C(N)=NNC=1C(F)(F)F YTARZCOGKBEMSD-UHFFFAOYSA-N 0.000 description 2
• 229920001817 Agar Polymers 0.000 description 2
• 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 101100037762 Caenorhabditis elegans rnh-2 gene Proteins 0.000 description 2
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
• 206010008342 Cervix carcinoma Diseases 0.000 description 2
• 206010009944 Colon cancer Diseases 0.000 description 2
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
• 241000194031 Enterococcus faecium Species 0.000 description 2
• 241000588724 Escherichia coli Species 0.000 description 2
• 241000495778 Escherichia faecalis Species 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
• 241000701806 Human papillomavirus Species 0.000 description 2
• 208000010159 IgA glomerulonephritis Diseases 0.000 description 2
• 206010021263 IgA nephropathy Diseases 0.000 description 2
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
• 240000007472 Leucaena leucocephala Species 0.000 description 2
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
• 241000699666 Mus <mouse, genus> Species 0.000 description 2
• HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
• WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
• CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
• 241000193998 Streptococcus pneumoniae Species 0.000 description 2
• 241000193996 Streptococcus pyogenes Species 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 241000223105 Trypanosoma brucei Species 0.000 description 2
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
• 239000008272 agar Substances 0.000 description 2
• 125000002947 alkylene group Chemical group 0.000 description 2
• 150000001448 anilines Chemical class 0.000 description 2
• 239000005557 antagonist Substances 0.000 description 2
• 230000000879 anti-atherosclerotic effect Effects 0.000 description 2
• 229940127219 anticoagulant drug Drugs 0.000 description 2
• 229940125708 antidiabetic agent Drugs 0.000 description 2
• 239000003472 antidiabetic agent Substances 0.000 description 2
• 239000002246 antineoplastic agent Substances 0.000 description 2
• 239000003963 antioxidant agent Substances 0.000 description 2
• 229960004676 antithrombotic agent Drugs 0.000 description 2
• 125000004429 atom Chemical group 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical class ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
• 230000003115 biocidal effect Effects 0.000 description 2
• 125000001108 carbamothioyl group Chemical group C(N)(=S)* 0.000 description 2
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
• 150000001768 cations Chemical class 0.000 description 2
• 201000010881 cervical cancer Diseases 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 208000037976 chronic inflammation Diseases 0.000 description 2
• 208000029742 colonic neoplasm Diseases 0.000 description 2
• 125000004122 cyclic group Chemical group 0.000 description 2
• 125000000753 cycloalkyl group Chemical group 0.000 description 2
• 231100000135 cytotoxicity Toxicity 0.000 description 2
• 230000003013 cytotoxicity Effects 0.000 description 2
• 210000004696 endometrium Anatomy 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• 235000003599 food sweetener Nutrition 0.000 description 2
• 230000006870 function Effects 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 235000011187 glycerol Nutrition 0.000 description 2
• 239000001963 growth medium Substances 0.000 description 2
• 150000002429 hydrazines Chemical class 0.000 description 2
• 150000002430 hydrocarbons Chemical class 0.000 description 2
• 150000004679 hydroxides Chemical class 0.000 description 2
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
• 210000002865 immune cell Anatomy 0.000 description 2
• 229960003444 immunosuppressant agent Drugs 0.000 description 2
• 230000001861 immunosuppressant effect Effects 0.000 description 2
• 239000003018 immunosuppressive agent Substances 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 201000006747 infectious mononucleosis Diseases 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 230000003834 intracellular effect Effects 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 239000002960 lipid emulsion Substances 0.000 description 2
• 150000002632 lipids Chemical class 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• 239000007937 lozenge Substances 0.000 description 2
• 201000005202 lung cancer Diseases 0.000 description 2
• 208000020816 lung neoplasm Diseases 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 239000002609 medium Substances 0.000 description 2
• 201000001441 melanoma Diseases 0.000 description 2
• 238000000465 moulding Methods 0.000 description 2
• 208000010125 myocardial infarction Diseases 0.000 description 2
• 230000003287 optical effect Effects 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 229910052760 oxygen Inorganic materials 0.000 description 2
• 239000001301 oxygen Substances 0.000 description 2
• 230000009589 pathological growth Effects 0.000 description 2
• 230000036470 plasma concentration Effects 0.000 description 2
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
• 229940069328 povidone Drugs 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 230000035755 proliferation Effects 0.000 description 2
• FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 2
• 125000006239 protecting group Chemical group 0.000 description 2
• 230000002685 pulmonary effect Effects 0.000 description 2
• 238000000746 purification Methods 0.000 description 2
• 230000002829 reductive effect Effects 0.000 description 2
• 230000025915 regulation of apoptotic process Effects 0.000 description 2
• 201000003068 rheumatic fever Diseases 0.000 description 2
• 230000001235 sensitizing effect Effects 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 230000003595 spectral effect Effects 0.000 description 2
• 239000007921 spray Substances 0.000 description 2
• 238000003756 stirring Methods 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 229910052717 sulfur Inorganic materials 0.000 description 2
• 239000000829 suppository Substances 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• 239000003765 sweetening agent Substances 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
• 239000002562 thickening agent Substances 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• 239000012049 topical pharmaceutical composition Substances 0.000 description 2
• 231100000419 toxicity Toxicity 0.000 description 2
• 230000001988 toxicity Effects 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 201000008827 tuberculosis Diseases 0.000 description 2
• 208000019553 vascular disease Diseases 0.000 description 2
• 239000012224 working solution Substances 0.000 description 2
• LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
• 125000006564 (C4-C8) cycloalkyl group Chemical group 0.000 description 1
• QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
• HKCFTGZESMCKJA-UHFFFAOYSA-N 1-pyridin-4-ylimidazolidin-2-one Chemical compound O=C1NCCN1C1=CC=NC=C1 HKCFTGZESMCKJA-UHFFFAOYSA-N 0.000 description 1
• LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
• NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
• NYPYHUZRZVSYKL-UHFFFAOYSA-N 2-azaniumyl-3-(4-hydroxy-3,5-diiodophenyl)propanoate Chemical compound OC(=O)C(N)CC1=CC(I)=C(O)C(I)=C1 NYPYHUZRZVSYKL-UHFFFAOYSA-N 0.000 description 1
• SFAAOBGYWOUHLU-UHFFFAOYSA-N 2-ethylhexyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC SFAAOBGYWOUHLU-UHFFFAOYSA-N 0.000 description 1
• 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 1
• 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
• RPQWXGVZELKOEU-UHFFFAOYSA-N 3,4-difluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C=C1F RPQWXGVZELKOEU-UHFFFAOYSA-N 0.000 description 1
• XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 1
• LPIFAHAICWJMRR-UHFFFAOYSA-N 3-chloro-5-fluoroaniline Chemical compound NC1=CC(F)=CC(Cl)=C1 LPIFAHAICWJMRR-UHFFFAOYSA-N 0.000 description 1
• ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
• KJTRXVXWSSPHRV-UHFFFAOYSA-N 4-benzoyl-5-methyl-2-phenyl-1h-pyrazol-3-one Chemical compound O=C1C(C(=O)C=2C=CC=CC=2)=C(C)NN1C1=CC=CC=C1 KJTRXVXWSSPHRV-UHFFFAOYSA-N 0.000 description 1
• HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
• 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
• 239000005541 ACE inhibitor Substances 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 206010002388 Angina unstable Diseases 0.000 description 1
• 200000000007 Arterial disease Diseases 0.000 description 1
• 206010003178 Arterial thrombosis Diseases 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 206010003658 Atrial Fibrillation Diseases 0.000 description 1
• 208000003950 B-cell lymphoma Diseases 0.000 description 1
• 241000193830 Bacillus <bacterium> Species 0.000 description 1
• 206010004146 Basal cell carcinoma Diseases 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 206010051779 Bone marrow toxicity Diseases 0.000 description 1
• 241000588832 Bordetella pertussis Species 0.000 description 1
• 241000589968 Borrelia Species 0.000 description 1
• 241000589969 Borreliella burgdorferi Species 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• 208000011691 Burkitt lymphomas Diseases 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• 239000004358 Butane-1, 3-diol Substances 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
• BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
• 229940127291 Calcium channel antagonist Drugs 0.000 description 1
• 241000589876 Campylobacter Species 0.000 description 1
• 241000589875 Campylobacter jejuni Species 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
• OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
• 206010008088 Cerebral artery embolism Diseases 0.000 description 1
• 206010008132 Cerebral thrombosis Diseases 0.000 description 1
• 240000001817 Cereus hexagonus Species 0.000 description 1
• 241000606161 Chlamydia Species 0.000 description 1
• 241001647372 Chlamydia pneumoniae Species 0.000 description 1
• 241001647378 Chlamydia psittaci Species 0.000 description 1
• 241000606153 Chlamydia trachomatis Species 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 241000193163 Clostridioides difficile Species 0.000 description 1
• 241000193403 Clostridium Species 0.000 description 1
• 241000193155 Clostridium botulinum Species 0.000 description 1
• 241000193468 Clostridium perfringens Species 0.000 description 1
• 241000193449 Clostridium tetani Species 0.000 description 1
• 244000060011 Cocos nucifera Species 0.000 description 1
• 235000013162 Cocos nucifera Nutrition 0.000 description 1
• 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
• 229920002785 Croscarmellose sodium Polymers 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 208000002249 Diabetes Complications Diseases 0.000 description 1
• 206010012655 Diabetic complications Diseases 0.000 description 1
• 206010014498 Embolic stroke Diseases 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 206010015278 Erythrodermic psoriasis Diseases 0.000 description 1
• 241000588722 Escherichia Species 0.000 description 1
• 241000282324 Felis Species 0.000 description 1
• 102000008946 Fibrinogen Human genes 0.000 description 1
• 108010049003 Fibrinogen Proteins 0.000 description 1
• 208000001640 Fibromyalgia Diseases 0.000 description 1
• 239000004606 Fillers/Extenders Substances 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• 102000020897 Formins Human genes 0.000 description 1
• 108091022623 Formins Proteins 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
• 208000003807 Graves Disease Diseases 0.000 description 1
• 108010051696 Growth Hormone Proteins 0.000 description 1
• 241000606790 Haemophilus Species 0.000 description 1
• 241000606768 Haemophilus influenzae Species 0.000 description 1
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
• 241000589989 Helicobacter Species 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 229940127517 Hormone Receptor Modulators Drugs 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• 102000004157 Hydrolases Human genes 0.000 description 1
• 108090000604 Hydrolases Proteins 0.000 description 1
• 206010020608 Hypercoagulation Diseases 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
• 101710149643 Integrin alpha-IIb Proteins 0.000 description 1
• 206010022562 Intermittent claudication Diseases 0.000 description 1
• 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
• 208000008839 Kidney Neoplasms Diseases 0.000 description 1
• 241000588748 Klebsiella Species 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 241000589248 Legionella Species 0.000 description 1
• 241000589242 Legionella pneumophila Species 0.000 description 1
• 241000186781 Listeria Species 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• 102000003979 Mineralocorticoid Receptors Human genes 0.000 description 1
• 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 1
• 241000588621 Moraxella Species 0.000 description 1
• 241000588622 Moraxella bovis Species 0.000 description 1
• 241000588655 Moraxella catarrhalis Species 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• 241001508003 Mycobacterium abscessus Species 0.000 description 1
• 241001467553 Mycobacterium africanum Species 0.000 description 1
• 241001134667 Mycobacterium celatum Species 0.000 description 1
• 241000187478 Mycobacterium chelonae Species 0.000 description 1
• 241001509451 Mycobacterium genavense Species 0.000 description 1
• 241000187484 Mycobacterium gordonae Species 0.000 description 1
• 241001147828 Mycobacterium haemophilum Species 0.000 description 1
• 241000186363 Mycobacterium kansasii Species 0.000 description 1
• 241000186362 Mycobacterium leprae Species 0.000 description 1
• 241000187493 Mycobacterium malmoense Species 0.000 description 1
• 241000187492 Mycobacterium marinum Species 0.000 description 1
• 241000187490 Mycobacterium scrofulaceum Species 0.000 description 1
• 241000187489 Mycobacterium simiae Species 0.000 description 1
• 241000187496 Mycobacterium szulgai Species 0.000 description 1
• 241000187494 Mycobacterium xenopi Species 0.000 description 1
• 241000204031 Mycoplasma Species 0.000 description 1
• 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 description 1
• 229910017852 NH2NH2 Inorganic materials 0.000 description 1
• 241000588653 Neisseria Species 0.000 description 1
• 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
• 241000588650 Neisseria meningitidis Species 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
• 201000010133 Oligodendroglioma Diseases 0.000 description 1
• 102000043276 Oncogene Human genes 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 206010033128 Ovarian cancer Diseases 0.000 description 1
• 206010061535 Ovarian neoplasm Diseases 0.000 description 1
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
• 102100037600 P2Y purinoceptor 1 Human genes 0.000 description 1
• 108050008996 P2Y purinoceptor 1 Proteins 0.000 description 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
• 208000031481 Pathologic Constriction Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 229920001214 Polysorbate 60 Polymers 0.000 description 1
• 229940127315 Potassium Channel Openers Drugs 0.000 description 1
• 201000001068 Prinzmetal angina Diseases 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 241000589516 Pseudomonas Species 0.000 description 1
• 208000010378 Pulmonary Embolism Diseases 0.000 description 1
• 206010037575 Pustular psoriasis Diseases 0.000 description 1
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
• 101100439111 Rattus norvegicus Cebpd gene Proteins 0.000 description 1
• 208000015634 Rectal Neoplasms Diseases 0.000 description 1
• 206010038389 Renal cancer Diseases 0.000 description 1
• 208000017442 Retinal disease Diseases 0.000 description 1
• 201000000582 Retinoblastoma Diseases 0.000 description 1
• 206010038923 Retinopathy Diseases 0.000 description 1
• 241000606701 Rickettsia Species 0.000 description 1
• 241000606697 Rickettsia prowazekii Species 0.000 description 1
• 241000606695 Rickettsia rickettsii Species 0.000 description 1
• 241000607142 Salmonella Species 0.000 description 1
• 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
• 241000607768 Shigella Species 0.000 description 1
• 241000607760 Shigella sonnei Species 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 206010041067 Small cell lung cancer Diseases 0.000 description 1
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 102000052126 Sodium-Hydrogen Exchangers Human genes 0.000 description 1
• 108091006672 Sodium–hydrogen antiporter Proteins 0.000 description 1
• 102100038803 Somatotropin Human genes 0.000 description 1
• NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
• 208000007718 Stable Angina Diseases 0.000 description 1
• 241000295644 Staphylococcaceae Species 0.000 description 1
• 208000005718 Stomach Neoplasms Diseases 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
• 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
• 206010042971 T-cell lymphoma Diseases 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• STSCVKRWJPWALQ-UHFFFAOYSA-N TRIFLUOROACETIC ACID ETHYL ESTER Chemical compound CCOC(=O)C(F)(F)F STSCVKRWJPWALQ-UHFFFAOYSA-N 0.000 description 1
• 208000024313 Testicular Neoplasms Diseases 0.000 description 1
• ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
• 102000003938 Thromboxane Receptors Human genes 0.000 description 1
• 108090000300 Thromboxane Receptors Proteins 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 206010052779 Transplant rejections Diseases 0.000 description 1
• 241000589886 Treponema Species 0.000 description 1
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
• 208000007814 Unstable Angina Diseases 0.000 description 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
• 208000002495 Uterine Neoplasms Diseases 0.000 description 1
• 208000009325 Variant Angina Pectoris Diseases 0.000 description 1
• 208000032594 Vascular Remodeling Diseases 0.000 description 1
• 206010047249 Venous thrombosis Diseases 0.000 description 1
• 206010047295 Ventricular hypertrophy Diseases 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 208000014070 Vestibular schwannoma Diseases 0.000 description 1
• 241000607598 Vibrio Species 0.000 description 1
• 241000607626 Vibrio cholerae Species 0.000 description 1
• 206010047642 Vitiligo Diseases 0.000 description 1
• 241000607734 Yersinia <bacteria> Species 0.000 description 1
• 241000607447 Yersinia enterocolitica Species 0.000 description 1
• 241000607477 Yersinia pseudotuberculosis Species 0.000 description 1
• FUASJQSBFUVWJQ-UHFFFAOYSA-N [N].NC(N)=N Chemical group [N].NC(N)=N FUASJQSBFUVWJQ-UHFFFAOYSA-N 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• 208000004064 acoustic neuroma Diseases 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 230000006786 activation induced cell death Effects 0.000 description 1
• 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
• 208000009956 adenocarcinoma Diseases 0.000 description 1
• 239000000853 adhesive Substances 0.000 description 1
• 230000001070 adhesive effect Effects 0.000 description 1
• WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 229940083712 aldosterone antagonist Drugs 0.000 description 1
• 229940072056 alginate Drugs 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 150000001340 alkali metals Chemical class 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• 125000005907 alkyl ester group Chemical group 0.000 description 1
• AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• 239000012491 analyte Substances 0.000 description 1
• 239000000587 angiogenesis modulating agent Substances 0.000 description 1
• 229940076002 angiogenesis modulator Drugs 0.000 description 1
• 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 150000001450 anions Chemical class 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 230000001093 anti-cancer Effects 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 230000000845 anti-microbial effect Effects 0.000 description 1
• 239000000883 anti-obesity agent Substances 0.000 description 1
• 230000003262 anti-osteoporosis Effects 0.000 description 1
• 230000001028 anti-proliverative effect Effects 0.000 description 1
• 230000000767 anti-ulcer Effects 0.000 description 1
• 239000003416 antiarrhythmic agent Substances 0.000 description 1
• 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
• 239000003529 anticholesteremic agent Substances 0.000 description 1
• 239000000935 antidepressant agent Substances 0.000 description 1
• 229940005513 antidepressants Drugs 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 229960005475 antiinfective agent Drugs 0.000 description 1
• 239000003524 antilipemic agent Substances 0.000 description 1
• 239000004599 antimicrobial Substances 0.000 description 1
• 229940125710 antiobesity agent Drugs 0.000 description 1
• 229940127218 antiplatelet drug Drugs 0.000 description 1
• 239000000164 antipsychotic agent Substances 0.000 description 1
• 239000003443 antiviral agent Substances 0.000 description 1
• 239000002249 anxiolytic agent Substances 0.000 description 1
• 239000008346 aqueous phase Substances 0.000 description 1
• 239000003125 aqueous solvent Substances 0.000 description 1
• 206010003119 arrhythmia Diseases 0.000 description 1
• 238000009246 art therapy Methods 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• 230000003143 atherosclerotic effect Effects 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
• 230000005784 autoimmunity Effects 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
• 229940092714 benzenesulfonic acid Drugs 0.000 description 1
• 229940050390 benzoate Drugs 0.000 description 1
• 229940049706 benzodiazepine Drugs 0.000 description 1
• 125000002619 bicyclic group Chemical group 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 238000011953 bioanalysis Methods 0.000 description 1
• 238000005842 biochemical reaction Methods 0.000 description 1
• 239000003124 biologic agent Substances 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 239000012503 blood component Substances 0.000 description 1
• 230000036765 blood level Effects 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 231100000366 bone marrow toxicity Toxicity 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 235000019437 butane-1,3-diol Nutrition 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000000480 calcium channel blocker Substances 0.000 description 1
• 238000011088 calibration curve Methods 0.000 description 1
• MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
• 208000035269 cancer or benign tumor Diseases 0.000 description 1
• 125000002837 carbocyclic group Chemical group 0.000 description 1
• 125000004432 carbon atom Chemical group C* 0.000 description 1
• 235000011089 carbon dioxide Nutrition 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 201000011529 cardiovascular cancer Diseases 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 230000020411 cell activation Effects 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 229940082500 cetostearyl alcohol Drugs 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 239000013043 chemical agent Substances 0.000 description 1
• 238000004296 chiral HPLC Methods 0.000 description 1
• 238000000633 chiral stationary phase gas chromatography Methods 0.000 description 1
• 229910052801 chlorine Chemical group 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 230000006020 chronic inflammation Effects 0.000 description 1
• 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 230000001332 colony forming effect Effects 0.000 description 1
• 238000004040 coloring Methods 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 229940125904 compound 1 Drugs 0.000 description 1
• 239000007891 compressed tablet Substances 0.000 description 1
• 230000001010 compromised effect Effects 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• 210000001608 connective tissue cell Anatomy 0.000 description 1
• 238000011109 contamination Methods 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 208000029078 coronary artery disease Diseases 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 239000002537 cosmetic Substances 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 239000007822 coupling agent Substances 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
• 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 150000001924 cycloalkanes Chemical class 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 238000004163 cytometry Methods 0.000 description 1
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 231100000599 cytotoxic agent Toxicity 0.000 description 1
• 239000002619 cytotoxin Substances 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000007123 defense Effects 0.000 description 1
• 230000003412 degenerative effect Effects 0.000 description 1
• 238000002716 delivery method Methods 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 231100000223 dermal penetration Toxicity 0.000 description 1
• 239000002274 desiccant Substances 0.000 description 1
• 229910052805 deuterium Inorganic materials 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 238000007865 diluting Methods 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 230000008034 disappearance Effects 0.000 description 1
• 231100000676 disease causative agent Toxicity 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
• 239000002934 diuretic Substances 0.000 description 1
• 229940030606 diuretics Drugs 0.000 description 1
• MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
• 229940043264 dodecyl sulfate Drugs 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 238000000132 electrospray ionisation Methods 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 239000008387 emulsifying waxe Substances 0.000 description 1
• 238000005538 encapsulation Methods 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 239000002702 enteric coating Substances 0.000 description 1
• 238000009505 enteric coating Methods 0.000 description 1
• 230000000369 enteropathogenic effect Effects 0.000 description 1
• 230000000688 enterotoxigenic effect Effects 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 210000000981 epithelium Anatomy 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 239000003889 eye drop Substances 0.000 description 1
• 229940012356 eye drops Drugs 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 230000008175 fetal development Effects 0.000 description 1
• 231100000562 fetal loss Toxicity 0.000 description 1
• 229940012952 fibrinogen Drugs 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 239000000706 filtrate Substances 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 229910052731 fluorine Inorganic materials 0.000 description 1
• 239000011737 fluorine Chemical group 0.000 description 1
• 239000006260 foam Substances 0.000 description 1
• 235000013373 food additive Nutrition 0.000 description 1
• 239000002778 food additive Substances 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 230000008014 freezing Effects 0.000 description 1
• 238000007710 freezing Methods 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 206010017758 gastric cancer Diseases 0.000 description 1
• 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 229940075507 glyceryl monostearate Drugs 0.000 description 1
• 239000000122 growth hormone Substances 0.000 description 1
• 239000003324 growth hormone secretagogue Substances 0.000 description 1
• 206010018797 guttate psoriasis Diseases 0.000 description 1
• 208000007475 hemolytic anemia Diseases 0.000 description 1
• 230000002949 hemolytic effect Effects 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 231100000283 hepatitis Toxicity 0.000 description 1
• MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
• 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 238000002657 hormone replacement therapy Methods 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
• 206010020718 hyperplasia Diseases 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 238000002664 inhalation therapy Methods 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 230000000266 injurious effect Effects 0.000 description 1
• 238000011081 inoculation Methods 0.000 description 1
• 239000002054 inoculum Substances 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
• 208000021156 intermittent vascular claudication Diseases 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 201000010849 intracranial embolism Diseases 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 229910052742 iron Inorganic materials 0.000 description 1
• 230000002530 ischemic preconditioning effect Effects 0.000 description 1
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
• 229940078545 isocetyl stearate Drugs 0.000 description 1
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
• 210000004731 jugular vein Anatomy 0.000 description 1
• 201000010982 kidney cancer Diseases 0.000 description 1
• 208000017169 kidney disease Diseases 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 230000021633 leukocyte mediated immunity Effects 0.000 description 1
• 201000011486 lichen planus Diseases 0.000 description 1
• 235000021388 linseed oil Nutrition 0.000 description 1
• 239000000944 linseed oil Substances 0.000 description 1
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
• 229940057995 liquid paraffin Drugs 0.000 description 1
• 201000007270 liver cancer Diseases 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 206010027191 meningioma Diseases 0.000 description 1
• 230000005906 menstruation Effects 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• 210000001872 metatarsal bone Anatomy 0.000 description 1
• 238000013048 microbiological method Methods 0.000 description 1
• 239000003094 microcapsule Substances 0.000 description 1
• 239000011859 microparticle Substances 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 239000002394 mineralocorticoid antagonist Substances 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 239000007932 molded tablet Substances 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
• 210000005087 mononuclear cell Anatomy 0.000 description 1
• 239000002324 mouth wash Substances 0.000 description 1
• 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
• 208000002089 myocardial stunning Diseases 0.000 description 1
• 229940043348 myristyl alcohol Drugs 0.000 description 1
• ZSIFRCPTEDRJBY-UHFFFAOYSA-N n-[(3-chloro-5-fluoroanilino)-[[4-methyl-5-(trifluoromethyl)-1h-pyrazol-3-yl]amino]methylidene]-3,4-difluorobenzamide Chemical compound N1C(C(F)(F)F)=C(C)C(NC(NC=2C=C(Cl)C=C(F)C=2)=NC(=O)C=2C=C(F)C(F)=CC=2)=N1 ZSIFRCPTEDRJBY-UHFFFAOYSA-N 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
• 239000007923 nasal drop Substances 0.000 description 1
• 239000007922 nasal spray Substances 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 208000025189 neoplasm of testis Diseases 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 231100000417 nephrotoxicity Toxicity 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 201000001119 neuropathy Diseases 0.000 description 1
• 230000007823 neuropathy Effects 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• 150000002825 nitriles Chemical class 0.000 description 1
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
• 108020004707 nucleic acids Proteins 0.000 description 1
• 102000039446 nucleic acids Human genes 0.000 description 1
• 150000007523 nucleic acids Chemical class 0.000 description 1
• 238000011580 nude mouse model Methods 0.000 description 1
• GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
• 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 239000003883 ointment base Substances 0.000 description 1
• 238000002515 oligonucleotide synthesis Methods 0.000 description 1
• 229940127234 oral contraceptive Drugs 0.000 description 1
• 239000003539 oral contraceptive agent Substances 0.000 description 1
• 238000003305 oral gavage Methods 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 201000002528 pancreatic cancer Diseases 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 208000003154 papilloma Diseases 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 235000010603 pastilles Nutrition 0.000 description 1
• 230000007918 pathogenicity Effects 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 230000000737 periodic effect Effects 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 208000033808 peripheral neuropathy Diseases 0.000 description 1
• JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 239000008251 pharmaceutical emulsion Substances 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
• 239000002953 phosphate buffered saline Substances 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 239000011574 phosphorus Chemical group 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 229940075930 picrate Drugs 0.000 description 1
• OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 229950010765 pivalate Drugs 0.000 description 1
• IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
• 230000007505 plaque formation Effects 0.000 description 1
• 239000003495 polar organic solvent Substances 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 238000003752 polymerase chain reaction Methods 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
• 239000002244 precipitate Substances 0.000 description 1
• 230000001376 precipitating effect Effects 0.000 description 1
• 230000035935 pregnancy Effects 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 235000013772 propylene glycol Nutrition 0.000 description 1
• 238000003908 quality control method Methods 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 230000035484 reaction time Effects 0.000 description 1
• 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
• 102000005962 receptors Human genes 0.000 description 1
• 108020003175 receptors Proteins 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 206010038038 rectal cancer Diseases 0.000 description 1
• 201000001275 rectum cancer Diseases 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 230000008672 reprogramming Effects 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 208000037803 restenosis Diseases 0.000 description 1
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
• 229960001860 salicylate Drugs 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 238000007493 shaping process Methods 0.000 description 1
• 235000020183 skimmed milk Nutrition 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 239000010802 sludge Substances 0.000 description 1
• 208000000587 small cell lung carcinoma Diseases 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
• 239000008109 sodium starch glycolate Substances 0.000 description 1
• 229940079832 sodium starch glycolate Drugs 0.000 description 1
• 229920003109 sodium starch glycolate Polymers 0.000 description 1
• 229910052938 sodium sulfate Inorganic materials 0.000 description 1
• 235000011152 sodium sulphate Nutrition 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 235000010356 sorbitol Nutrition 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 238000012289 standard assay Methods 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 230000036262 stenosis Effects 0.000 description 1
• 208000037804 stenosis Diseases 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 201000011549 stomach cancer Diseases 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 150000005846 sugar alcohols Polymers 0.000 description 1
• 239000011593 sulfur Chemical group 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 201000010965 sweat gland carcinoma Diseases 0.000 description 1
• 210000000225 synapse Anatomy 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 230000009897 systematic effect Effects 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 201000003120 testicular cancer Diseases 0.000 description 1
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
• OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
• 230000009424 thromboembolic effect Effects 0.000 description 1
• 201000005665 thrombophilia Diseases 0.000 description 1
• 201000002510 thyroid cancer Diseases 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 238000003354 tissue distribution assay Methods 0.000 description 1
• 210000003371 toe Anatomy 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• 239000006150 trypticase soy agar Substances 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
• ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• 206010046766 uterine cancer Diseases 0.000 description 1
• 239000013598 vector Substances 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 230000002861 ventricular Effects 0.000 description 1
• 230000035899 viability Effects 0.000 description 1
• 238000012800 visualization Methods 0.000 description 1
• 239000011782 vitamin Substances 0.000 description 1
• 235000013343 vitamin Nutrition 0.000 description 1
• 229940088594 vitamin Drugs 0.000 description 1
• 229930003231 vitamin Natural products 0.000 description 1
• 239000003643 water by type Substances 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 238000010626 work up procedure Methods 0.000 description 1